Beyfortus(Nirsevlmab-alip)-AAP Recommendations for the Prevention of RSV Disease in Infants and Children. 니르세비맙은 2023년 7월 17일 미국 식품의약국(FDA)의 승인을 받았습니다.
Beyfortus(Nirsevimab )-AAP Recommendations for the Prevention of RSV Disease in Infants and Children February 21, 2024 Nirsevimab was approved by the US Food and Drug Administration (FDA) on July 17, 2023. Nirsevimab is a long-acting monoclonal antibody product intended for … Continued